# AI Management Framework (AIMF) by PraeSyn
## Framework Profile: Healthcare

**© 2026 PraeSyn, LLC. All rights reserved.**
Licensed under CC BY-NC-ND 4.0

**Profile Identifier**: AIMF-FP-HEALTHCARE
**Version**: 1.0
**Publication Date**: January 29, 2026
**Intended Use**: Healthcare organizations deploying patient-facing and clinical AI
**Baseline Applicability**: B2-B3 (risk-dependent; diagnostic AI typically B3)
**Default Target Maturity**: ML3 (Defined); ML4 for safety and privacy controls
**Status**: Pre-Publication (Working Draft)

---

## Profile Overview

### Purpose
The Healthcare Profile addresses requirements for healthcare organizations deploying AI in clinical, operational, and administrative settings. Emphasizes patient safety, privacy (HIPAA), explainability for clinicians, and data quality for diagnostic accuracy.

### Scope
- **Target Organizations**: Hospitals, clinics, diagnostic centers, health plans, healthcare technology companies
- **AI Systems**: Diagnostic AI, clinical decision support, patient monitoring, health records AI, administrative AI
- **Regulatory Drivers**: HIPAA, FDA regulations, patient safety standards, clinical practice guidelines
- **Implementation Timeline**: 9-18 months with clinical + governance teams

---

## Control Selection Summary

| Function | Controls | Key Focus Areas |
|----------|----------|-----------------|
| GOVERN   | 16/19    | Safety culture, stakeholder engagement, diversity (clinical + technical teams) |
| MAP      | 16/19    | Clinical requirements, team composition, impact on patient outcomes |
| MEASURE  | 19/22    | Safety, privacy, explainability, human evaluation (clinical validation) |
| MANAGE   | 11/13    | Clinical oversight, incident response, continuous improvement |
| **Total**| **62/72**| **85% coverage with healthcare emphasis** |

---

## Key Regulatory Requirements

### Federal Regulations
- **HIPAA**: Privacy and security of protected health information (PHI)
- **FDA**: Medical device regulations for diagnostic/therapeutic AI (21 CFR Part 880, Software as Medical Device)
- **CLIA**: Clinical Laboratory Improvement Amendments (for diagnostic AI)

### Standards & Guidelines
- **Clinical Practice Guidelines**: Integration with evidence-based medicine
- **HL7/FHIR**: Health data interoperability standards
- **Patient Safety Standards**: Alignment with Joint Commission, state health departments

---

## Industry-Specific Control Emphases

### Patient Safety (PARAMOUNT)
**Controls**: MEA-2.6 (Safety Evaluation), MAP-2.2 (System Boundaries), MAP-3.5 (Human Oversight)
**B2-B3 Requirements**:
- Comprehensive safety evaluation with clinical experts
- Fail-safe mechanisms for critical systems
- Clear boundaries on AI recommendations vs clinical decisions
- Mandatory clinician oversight for high-risk AI
- Incident reporting integrated with patient safety systems

### Privacy & Security (HIPAA Compliance)
**Controls**: MEA-2.10 (Privacy Evaluation), MEA-2.7 (Security Assessment), GOV-1.1 (Legal Compliance)
**B2-B3 Requirements**:
- Privacy Impact Assessments (PIAs) for all PHI-processing AI
- HIPAA-compliant data handling and storage
- Security risk analysis (HIPAA Security Rule)
- Access controls and audit logging
- Breach notification procedures

### Clinical Explainability
**Controls**: MEA-2.9 (Model Explanation), MEA-2.8 (Transparency)
**B2-B3 Requirements**:
- Clinician-appropriate explanations (not just technical)
- Integration with clinical workflow
- Clear presentation of AI confidence/uncertainty
- Documentation for medical records
- Support for clinical accountability

### Data Quality & Validation
**Controls**: MAP-1.6 (Requirements), MEA-2.5 (Validity/Reliability), MEA-2.1 (Testing Documentation)
**B2-B3 Requirements**:
- Clinical validation with diverse patient populations
- Data quality standards for training data
- Generalizability assessment (population representativeness)
- Continuous validation in production
- Performance monitoring by patient demographic

### Human Subject Research
**Controls**: MEA-2.2 (Human Subject Testing), MAP-1.2 (Team Diversity)
**B2-B3 Requirements**:
- IRB (Institutional Review Board) oversight for research AI
- Informed consent for AI-involved care
- Patient protections aligned with Common Rule
- Representative sampling across patient demographics

---

## Implementation Phases

### Phase 1: Foundation & Clinical Integration (Months 1-3)
1. Establish Clinical AI Committee (clinician-led)
2. AI inventory with FDA/clinical risk classification
3. HIPAA compliance baseline for AI systems
4. Patient safety integration

### Phase 2: Clinical Validation (Months 3-9)
1. Clinical validation studies
2. Safety and effectiveness evaluation
3. Explainability for clinicians
4. Privacy and security audits

### Phase 3: Deployment & Monitoring (Months 9-18)
1. Clinical workflow integration
2. Continuous performance monitoring (by demographics)
3. Incident response (clinical + IT)
4. Ongoing FDA compliance (if applicable)

---

## FDA Considerations (Software as Medical Device)

**If AI qualifies as SaMD**:
- Pre-market approval or 510(k) clearance may be required
- AIMF aligns with FDA Total Product Lifecycle approach
- Quality Management System (QMS) integration
- Post-market surveillance requirements

**Profile Support**: AIMF controls map to FDA expectations for AI/ML quality and safety

---

## Success Criteria

- ✅ Patient safety incidents = 0 attributed to AI
- ✅ HIPAA compliance validated (annual audit)
- ✅ Clinical validation completed with diverse patients
- ✅ FDA compliance (if applicable)
- ✅ Clinician satisfaction with AI explainability
- ✅ IRB oversight for research AI

---

## Related Documents

- [AIMF Profiles Guide](../../implementation/AIMF-PROFILES-GUIDE.md)
- [Control Catalog](../../core/AIMF-CONTROL-CATALOG.md)

**AI Management Framework (AIMF) by PraeSyn**
